A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aortic valve replacement, a type of heart ...
Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aortic valve replacement, a type of heart ...
CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...
PARIS, France—A new analysis of more than 10,000 patients likely slams the door on routinely using cerebral embolic protection for stroke prevention in patients with aortic stenosis undergoing TAVI.
(MENAFN- GlobeNewsWire - Nasdaq) Key states, including California and Texas, lead in demand due to advanced healthcare systems and aging populations Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback